BACKGROUND AND PURPOSE: Because of a shortage of stroke specialists, many outlying or "spoke" hospitals initiate intravenous (IV) thrombolysis using telemedicine or telephone consultation before transferring patients to a regional stroke center (RSC) hub. We analyzed complications and outcomes of patients treated with IV tissue plasminogen activator (tPA) using the "drip and ship" approach compared to those treated directly at the RSC. METHODS: A retrospective review of our Get With the Guidelines Stroke (GWTG-Stroke) database from 01/2003 to 03/2008 identified 296 patients who received IV tPA within 3 hours of symptom onset without catheter-based reperfusion. GWTG-Stroke definitions for symptomatic intracranial (sICH), systemic hemorrhage, discharge functional status, and destination were applied. Follow-up modified Rankin Score was recorded when available. RESULTS: Of 296 patients, 181 (61.1%) had tPA infusion started at an outside spoke hospital (OSH) and 115 (38.9%) at the RSC hub. OSH patients were younger with fewer severe strokes than RSC patients. Patients treated based on telestroke were more frequently octogenarians than patients treated based on a telephone consult. Mortality, sICH, and functional outcomes were not different between OSH versus RSC and telephone versus telestroke patients. Among survivors, mean length of stay was shorter for OSH patients but discharge status was similar and 75% of patients walked independently at discharge. CONCLUSIONS: Outcomes in OSH "drip and ship" patients treated in a hub-and-spoke network were comparable to those treated directly at an RSC. These data suggest that "drip and ship" is a safe and effective method to shorten time to treatment with IV tPA.
BACKGROUND AND PURPOSE: Because of a shortage of stroke specialists, many outlying or "spoke" hospitals initiate intravenous (IV) thrombolysis using telemedicine or telephone consultation before transferring patients to a regional stroke center (RSC) hub. We analyzed complications and outcomes of patients treated with IV tissue plasminogen activator (tPA) using the "drip and ship" approach compared to those treated directly at the RSC. METHODS: A retrospective review of our Get With the Guidelines Stroke (GWTG-Stroke) database from 01/2003 to 03/2008 identified 296 patients who received IV tPA within 3 hours of symptom onset without catheter-based reperfusion. GWTG-Stroke definitions for symptomatic intracranial (sICH), systemic hemorrhage, discharge functional status, and destination were applied. Follow-up modified Rankin Score was recorded when available. RESULTS: Of 296 patients, 181 (61.1%) had tPA infusion started at an outside spoke hospital (OSH) and 115 (38.9%) at the RSC hub. OSH patients were younger with fewer severe strokes than RSCpatients. Patients treated based on telestroke were more frequently octogenarians than patients treated based on a telephone consult. Mortality, sICH, and functional outcomes were not different between OSH versus RSC and telephone versus telestrokepatients. Among survivors, mean length of stay was shorter for OSH patients but discharge status was similar and 75% of patients walked independently at discharge. CONCLUSIONS: Outcomes in OSH "drip and ship"patients treated in a hub-and-spoke network were comparable to those treated directly at an RSC. These data suggest that "drip and ship" is a safe and effective method to shorten time to treatment with IV tPA.
Authors: Lee H Schwamm; Heinrich J Audebert; Pierre Amarenco; Neale R Chumbler; Michael R Frankel; Mary G George; Philip B Gorelick; Katie B Horton; Markku Kaste; Daniel T Lackland; Steven R Levine; Brett C Meyer; Philip M Meyers; Victor Patterson; Steven K Stranne; Christopher J White Journal: Stroke Date: 2009-05-07 Impact factor: 7.914
Authors: M Fiorelli; S Bastianello; R von Kummer; G J del Zoppo; V Larrue; E Lesaffre; A P Ringleb; S Lorenzano; C Manelfe; L Bozzao Journal: Stroke Date: 1999-11 Impact factor: 7.914
Authors: J R Marler; B C Tilley; M Lu; T G Brott; P C Lyden; J C Grotta; J P Broderick; S R Levine; M P Frankel; S H Horowitz; E C Haley; C A Lewandowski; T P Kwiatkowski Journal: Neurology Date: 2000-12-12 Impact factor: 9.910
Authors: Sheryl Martin-Schild; Miriam M Morales; Aslam M Khaja; Andrew D Barreto; Hen Hallevi; Anitha Abraham; M Rick Sline; Elizabeth Jones; James C Grotta; Sean I Savitz Journal: J Emerg Med Date: 2009-03-09 Impact factor: 1.484
Authors: Sam Wang; Sung Bae Lee; Carol Pardue; Davinder Ramsingh; Jennifer Waller; Hartmut Gross; Fenwick T Nichols; David C Hess; Robert J Adams Journal: Stroke Date: 2003-09-18 Impact factor: 7.914
Authors: Lee H Schwamm; Robert G Holloway; Pierre Amarenco; Heinrich J Audebert; Tamilyn Bakas; Neale R Chumbler; Rene Handschu; Edward C Jauch; William A Knight; Steven R Levine; Marc Mayberg; Brett C Meyer; Philip M Meyers; Elaine Skalabrin; Lawrence R Wechsler Journal: Stroke Date: 2009-05-07 Impact factor: 7.914
Authors: Brian P Walcott; Jennifer C Miller; Churl-Su Kwon; Sameer A Sheth; Marc Hiller; Carolyn A Cronin; Lee H Schwamm; J Marc Simard; Kristopher T Kahle; W Taylor Kimberly; Kevin N Sheth Journal: Neurocrit Care Date: 2014-08 Impact factor: 3.210
Authors: Michael J Lyerly; Karen C Albright; Amelia K Boehme; Reza Bavarsad Shahripour; John P Donnelly; James T Houston; Pawan V Rawal; Niren Kapoor; Muhammad Alvi; April Sisson; Anne W Alexandrov; Andrei V Alexandrov Journal: South Med J Date: 2015-07 Impact factor: 0.954
Authors: Rashid L Bashshur; Gary W Shannon; Brian R Smith; Dale C Alverson; Nina Antoniotti; William G Barsan; Noura Bashshur; Edward M Brown; Molly J Coye; Charles R Doarn; Stewart Ferguson; Jim Grigsby; Elizabeth A Krupinski; Joseph C Kvedar; Jonathan Linkous; Ronald C Merrell; Thomas Nesbitt; Ronald Poropatich; Karen S Rheuban; Jay H Sanders; Andrew R Watson; Ronald S Weinstein; Peter Yellowlees Journal: Telemed J E Health Date: 2014-06-26 Impact factor: 3.536